New
Great news for the vitiligo community in the EU!
Incyte has just announced in a press-release that ruxolitinib cream (Opzelura™) has received a positive opinion from the European Medicines Agency (EMA) committee for the treatment of vitiligo with facial involvement.
The green light opens the fast track way for it to become the first ‘official’ vitiligo therapy available in the EU. Incyte has been eagerly awaiting approval in the EU ever since the it’s drug was registered by the US FDA in July 2022.
Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.
FAQOther Questions
- What's better: laser or phototherapy?
Both laser treatment and phototherapy are effective options for treating vitiligo, but they each have their own advantages and considerations: Laser Treatment Advantages:- Hig...
- How smoking affects vitiligo?
Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo ...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.